Sovesudil (hydrochloride)

Sovesudil (PHP-201) hydrochloride is a potent, ATP-competitive, locally acting Rho kinase (ROCK) inhibitor with IC50s of 3.7 and 2.3 nM for ROCK-I and ROCK-II, respectively. Sovesudil hydrochloride lowers intraocular pressure (IOP) without inducing hyperemia[1][2].

Product Specifications

CAS Number

[2984963-50-8]

Product Name Alternative

PHP-201 (hydrochloride) ; AMA0076 (hydrochloride)

UNSPSC

12352005

Target

ROCK

Type

Reference compound

Related Pathways

Cell Cycle/DNA Damage; Cytoskeleton; Stem Cell/Wnt; TGF-beta/Smad

Applications

Neuroscience-Neuromodulation

Field of Research

Neurological Disease

Assay Protocol

https://www.medchemexpress.com/sovesudil-hydrochloride.html

Purity

99.45

Solubility

DMSO : 62.5 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

O=C(C1=CC(C2=CC(C(NC3=C(F)C=NC=C3)=O)=CC=C2CN)=CC=C1)OCCC.[H]Cl

Molecular Formula

C23H23ClFN3O3

Molecular Weight

443.90

References & Citations

[1]Van de Velde S, et al. AMA0076, a novel, locally acting Rho kinase inhibitor, potently lowers intraocular pressure in New Zealand white rabbits with minimal hyperemia. Invest Ophthalmol Vis Sci. 2014;55 (2) :1006-1016. Published 2014 Feb 18. |[2]Ha A, et al. Sovesudil (locally acting rho kinase inhibitor) for the treatment of normal-tension glaucoma: the randomized phase II study [published online ahead of print, 2021 Jul 28]. Acta Ophthalmol. 2021;10.1111/aos.14949.